BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Mammen AL, Allenbach Y, Stenzel W, Benveniste O; ENMC 239th Workshop Study Group. 239th ENMC International Workshop: Classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018. Neuromuscul Disord 2020;30:70-92. [PMID: 31791867 DOI: 10.1016/j.nmd.2019.10.005] [Cited by in Crossref: 27] [Cited by in F6Publishing: 52] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Liu L, Wang J, Zhang P, Sun W, Zhu X, Sun X, Xue J, Wu H, Jinhui L. Promising Neutrophil-Associated Biomarkers in Lung Diseases of Patients with Antisynthetase Syndrome and Dermatomyositis. Journal of Immunology Research 2022;2022:1-11. [DOI: 10.1155/2022/1886083] [Reference Citation Analysis]
2 Zhao L, Huang W, Wang H, Chen J, Zhang D, Wang X, Sun F, Ye S. Two clusters of systemic lupus erythematosus patients with muscle involvement in a Chinese cohort. Int J Rheum Dis 2022. [PMID: 36117395 DOI: 10.1111/1756-185X.14443] [Reference Citation Analysis]
3 Lu X, Peng Q, Wang G. Biomarkers of disease activity in dermatomyositis. Curr Opin Rheumatol 2022. [PMID: 36082751 DOI: 10.1097/BOR.0000000000000905] [Reference Citation Analysis]
4 Xiong H, Tan Q, Luo F, Yuan X, Ma W, Yao X. Anti-MDA5 and anti-SSA/Ro52 antibodies double-positive dermatomyositis overlapping with rheumatoid arthritis-associated interstitial lung disease: A case report. Int J Rheum Dis 2022. [PMID: 36029141 DOI: 10.1111/1756-185X.14430] [Reference Citation Analysis]
5 Liu T, Li W, Zhang Z, Jiang T, Fei Y, Huang J, Xie Q. Neutrophil-to-lymphocyte ratio is a predictive marker for anti-MDA5 positive dermatomyositis. BMC Pulm Med 2022;22:316. [PMID: 35978395 DOI: 10.1186/s12890-022-02106-8] [Reference Citation Analysis]
6 Sun Y, Li DF, Zhang YL, Liang X, Li TF. Characterisation of Disease Patterns of Dermatomyositis with Different Initial Manifestations. Int J Gen Med 2022;15:6519-28. [PMID: 35971527 DOI: 10.2147/IJGM.S372658] [Reference Citation Analysis]
7 Tanboon J, Nishino I. Update on dermatomyositis. Curr Opin Neurol 2022. [PMID: 35942671 DOI: 10.1097/WCO.0000000000001091] [Reference Citation Analysis]
8 Liu Y, Hu M, Fan G, Xing N, Zhang R. Effect of Baricitinib on the epithelial-mesenchymal transition of alveolar epithelial cells induced by IL-6. Int Immunopharmacol 2022;110:109044. [PMID: 35850052 DOI: 10.1016/j.intimp.2022.109044] [Reference Citation Analysis]
9 Anderle K, Machold K, Kiener HP, Bormann D, Hoetzenecker K, Geleff S, Prosch H, Laccone F, Heil PM, Petzelbauer P, Aletaha D, Blüml S, Kastrati K. COVID-19 as a putative trigger of anti-MDA5-associated dermatomyositis with acute respiratory distress syndrome (ARDS) requiring lung transplantation, a case report. BMC Rheumatol 2022;6:42. [PMID: 35821079 DOI: 10.1186/s41927-022-00271-1] [Reference Citation Analysis]
10 Galindo-Feria AS, Wang G, Lundberg IE. Autoantibodies: Pathogenic or epiphenomenon. Best Pract Res Clin Rheumatol 2022;:101767. [PMID: 35810122 DOI: 10.1016/j.berh.2022.101767] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
11 Bhai SF, Dimachkie MM, de Visser M. Is it really myositis? Mimics and pitfalls. Best Pract Res Clin Rheumatol 2022;:101764. [PMID: 35752578 DOI: 10.1016/j.berh.2022.101764] [Reference Citation Analysis]
12 Preuße C, Paesler B, Nelke C, Cengiz D, Müntefering T, Roos A, Amelin D, Allenbach Y, Uruha A, Dittmayer C, Hentschel A, Pawlitzki M, Hoffmann S, Timm S, Louis SL, Dengler NF, Wiendl H, Lünemann JD, Sickmann A, Hervier B, Meuth SG, Schneider U, Schänzer A, Krause S, Tomaras S, Feist E, Hasseli R, Goebel HH, Gallay L, Streichenberger N, Benveniste O, Stenzel W, Ruck T. Skeletal muscle provides the immunological micro-milieu for specific plasma cells in anti-synthetase syndrome-associated myositis. Acta Neuropathol 2022. [PMID: 35612662 DOI: 10.1007/s00401-022-02438-z] [Reference Citation Analysis]
13 Zhou J, Zhao L, Xiao Y, Xie S, Long Y, Wei Y, Meng Q, Li X, Luo H, Zhu H. The Expression of Cytokine Profiles and Related Receptors in Idiopathic Inflammatory Myopathies. Front Pharmacol 2022;13:852055. [PMID: 35517781 DOI: 10.3389/fphar.2022.852055] [Reference Citation Analysis]
14 Yang H, Tian X, Zhang L, Li W, Liu Q, Jiang W, Peng Q, Wang G, Lu X. Clinical and pathological features of immune-mediated necrotising myopathies in a single-centre muscle biopsy cohort. BMC Musculoskelet Disord 2022;23:425. [PMID: 35524238 DOI: 10.1186/s12891-022-05372-z] [Reference Citation Analysis]
15 Chen F, Wang J, Zhang P, Zuo Y, Ye L, Wang G, Shu X. Interstitial Lung Disease in Dermatomyositis Without Myositis-Specific and Myositis-Associated Autoantibodies: Study of a Series of 72 Patients From a Single Cohort. Front Immunol 2022;13:879266. [DOI: 10.3389/fimmu.2022.879266] [Reference Citation Analysis]
16 Damoiseaux J, Mammen AL, Piette Y, Benveniste O, Allenbach Y. 256th ENMC international workshop: Myositis specific and associated autoantibodies (MSA-ab): Amsterdam, The Netherlands, 8-10 October 2021. Neuromuscular Disorders 2022. [DOI: 10.1016/j.nmd.2022.05.011] [Reference Citation Analysis]
17 Kamperman RG, van der Kooi AJ, de Visser M, Aronica E, Raaphorst J. Pathophysiological Mechanisms and Treatment of Dermatomyositis and Immune Mediated Necrotizing Myopathies: A Focused Review. Int J Mol Sci 2022;23:4301. [PMID: 35457124 DOI: 10.3390/ijms23084301] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
18 Ouyang Z, Lin J, Tang A, Yang Z, Yang L, Wei X, Li Q, Liang J, Zheng D, Guo B, Zhao G, Han Q, Dai L, Mo Y. A Matrix Prediction Model for the 6-Month Mortality Risk in Patients With Anti-Melanoma Differentiation-Associated Protein-5-Positive Dermatomyositis. Front Med 2022;9:860798. [DOI: 10.3389/fmed.2022.860798] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
19 Zhang S, Chen YL, Liu CL, Xie JY, Sun BD, Liu DZ. Case Report: IgA Nephropathy in a Patient With Anti-Transcription Intermediary Factor-1γ Antibody-Positive Dermatomyositis. Front Immunol 2022;13:757802. [PMID: 35185871 DOI: 10.3389/fimmu.2022.757802] [Reference Citation Analysis]
20 Zuo Y, Ye L, Chen F, Shen Y, Lu X, Wang G, Shu X. Different Multivariable Risk Factors for Rapid Progressive Interstitial Lung Disease in Anti-MDA5 Positive Dermatomyositis and Anti-Synthetase Syndrome. Front Immunol 2022;13:845988. [DOI: 10.3389/fimmu.2022.845988] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Bonroy C, Piette Y, Allenbach Y, Bossuyt X, Damoiseaux J. Positioning of myositis-specific and associated autoantibody (MSA/MAA) testing in disease criteria and routine diagnostic work-up. Journal of Translational Autoimmunity 2022. [DOI: 10.1016/j.jtauto.2022.100148] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
22 Xu W, Wu W, Zheng Y, Chen Z, Tao X, Zhang D, Zhao J, Wang K, Guo B, Luo Q, Han Q, Zhou Y, Ye S. A Computed Tomography Radiomics-Based Prediction Model on Interstitial Lung Disease in Anti-MDA5-Positive Dermatomyositis. Front Med (Lausanne) 2021;8:768052. [PMID: 34912828 DOI: 10.3389/fmed.2021.768052] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
23 Walter HAW, Kamperman RG, Raaphorst J, Verhamme C, Koelman JHTM, Potters WV, Hemke R, Smithuis FF, Aronica E, van Leeuwen EMM, Baars PA, de Visser M, van Schaik IN, Bossuyt PMM, van der Kooi AJ. OptimisAtion of Diagnostic Accuracy in idioPathic inflammaTory myopathies (ADAPT study): a protocol for a prospective diagnostic accuracy study of multimodality testing in patients suspected of a treatable idiopathic inflammatory myopathy. BMJ Open 2021;11:e053594. [PMID: 34903547 DOI: 10.1136/bmjopen-2021-053594] [Reference Citation Analysis]
24 Varadhachary AS. Recognition and Management of Neuromuscular Emergencies. Neurol Clin 2022;40:157-74. [PMID: 34798967 DOI: 10.1016/j.ncl.2021.08.010] [Reference Citation Analysis]
25 Zoske J, Schneider U, Siegert E, Kleefeld F, Preuße C, Stenzel W, Hahn K. Performance of ENMC and EULAR/ACR classification systems applied to a single tertiary center cohort of dermatomyositis patients. Neurol Res Pract 2021;3:59. [PMID: 34776008 DOI: 10.1186/s42466-021-00159-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Stenzel W, Goebel HH, Bader-Meunier B, Gitiaux C. Inflammatory myopathies in childhood. Neuromuscul Disord 2021;31:1051-61. [PMID: 34736626 DOI: 10.1016/j.nmd.2021.08.007] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
27 Wang K, Zhao J, Wu W, Xu W, Sun S, Chen Z, Fu Y, Guo L, Du H, Ye S. RNA-Containing Immune Complexes Formed by Anti-Melanoma Differentiation Associated Gene 5 Autoantibody Are Potent Inducers of IFN-α. Front Immunol 2021;12:743704. [PMID: 34721411 DOI: 10.3389/fimmu.2021.743704] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
28 Wang C, Du J, Mei X, Guo L, Li F, Luo H, Li F. The Value of Effective Lung Ventilation Area Ratio Based on CT Image Analysis Is a New Index to Predict the Shorter Outcome of Anti-melanoma Differentiation-Associated Protein 5 Positive Dermatomyositis Associated Interstitial Lung Disease: A Single-Center Retrospective Study. Front Med (Lausanne) 2021;8:728487. [PMID: 34692722 DOI: 10.3389/fmed.2021.728487] [Reference Citation Analysis]
29 Pawlitzki M, Nelke C, Rolfes L, Hasseli R, Tomaras S, Feist E, Schänzer A, Räuber S, Regner L, Preuße C, Allenbach Y, Benveniste O, Wiendl H, Stenzel W, Meuth SG, Ruck T. NK Cell Patterns in Idiopathic Inflammatory Myopathies with Pulmonary Affection. Cells 2021;10:2551. [PMID: 34685530 DOI: 10.3390/cells10102551] [Reference Citation Analysis]
30 Schneider U, Stenzel W, Stuhlmüller B. Biomarker und Histologie bei idiopathischen inflammatorischen Myopathien. Aktuelle Rheumatologie 2021;46:343-60. [DOI: 10.1055/a-1548-8934] [Reference Citation Analysis]
31 Fornaro M, Girolamo F, Cavagna L, Franceschini F, Giannini M, Amati A, Lia A, Tampoia M, D'Abbicco D, Maggi L, Fredi M, Zanframundo G, Moschetti L, Coladonato L, Iannone F. Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis. Rheumatology (Oxford) 2021;60:2916-26. [PMID: 33249503 DOI: 10.1093/rheumatology/keaa739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
32 Xu W, Wu W, Zhang D, Chen Z, Tao X, Zhao J, Wang K, Wang X, Zheng Y, Ye S. A novel CT scoring method predicts the prognosis of interstitial lung disease associated with anti-MDA5 positive dermatomyositis. Sci Rep 2021;11:17070. [PMID: 34426622 DOI: 10.1038/s41598-021-96292-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
33 Rodero MP, Pelleau S, Welfringer-Morin A, Duffy D, Melki I, Bader-Meunier B; FJDM study group., FJDM Study group. Onset and Relapse of Juvenile Dermatomyositis Following Asymptomatic SARS-CoV-2 Infection. J Clin Immunol 2021. [PMID: 34426906 DOI: 10.1007/s10875-021-01119-y] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
34 Aschman T, Schneider J, Greuel S, Meinhardt J, Streit S, Goebel HH, Büttnerova I, Elezkurtaj S, Scheibe F, Radke J, Meisel C, Drosten C, Radbruch H, Heppner FL, Corman VM, Stenzel W. Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died. JAMA Neurol 2021;78:948-60. [PMID: 34115106 DOI: 10.1001/jamaneurol.2021.2004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 37] [Article Influence: 1.0] [Reference Citation Analysis]
35 Wilkinson M, Yeung D, Limaye V. A case of inflammatory myopathy in graft vs host disease - A potential role for ibrutinib. Neuromuscul Disord 2021:S0960-8966(21)00177-2. [PMID: 34334272 DOI: 10.1016/j.nmd.2021.06.015] [Reference Citation Analysis]
36 Uruha A, Goebel HH, Stenzel W. Updates on the Immunopathology in Idiopathic Inflammatory Myopathies. Curr Rheumatol Rep 2021;23:56. [PMID: 34212266 DOI: 10.1007/s11926-021-01017-7] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
37 Siegert E, Uruha A, Goebel HH, Preuße C, Casteleyn V, Kleefeld F, Alten R, Burmester GR, Schneider U, Höppner J, Hahn K, Dittmayer C, Stenzel W. Systemic sclerosis-associated myositis features minimal inflammation and characteristic capillary pathology. Acta Neuropathol 2021;141:917-27. [PMID: 33864496 DOI: 10.1007/s00401-021-02305-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
38 Preusse C, Eede P, Heinzeling L, Freitag K, Koll R, Froehlich W, Schneider U, Allenbach Y, Benveniste O, Schänzer A, Goebel HH, Stenzel W, Radke J. NanoString technology distinguishes anti-TIF-1γ+ from anti-Mi-2+ dermatomyositis patients. Brain Pathol 2021;31:e12957. [PMID: 34043263 DOI: 10.1111/bpa.12957] [Cited by in Crossref: 1] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
39 Malartre S, Bachasson D, Mercy G, Sarkis E, Anquetil C, Benveniste O, Allenbach Y. MRI and muscle imaging for idiopathic inflammatory myopathies. Brain Pathol 2021;31:e12954. [PMID: 34043260 DOI: 10.1111/bpa.12954] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
40 Hou Y, Shao K, Yan Y, Dai T, Li W, Zhao Y, Li D, Lu JQ, Norman GL, Yan C. Anti-HMGCR myopathy overlaps with dermatomyositis-like rash: a distinct subtype of idiopathic inflammatory myopathy. J Neurol 2021. [PMID: 34021410 DOI: 10.1007/s00415-021-10621-7] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
41 Hou C, Durrleman C, Periou B, Barnerias C, Bodemer C, Desguerre I, Quartier P, Melki I, Rice GI, Rodero MP, Charuel J, Relaix F, Bader‐meunier B, Authier F, Gitiaux C. From Diagnosis to Prognosis: Revisiting the Meaning of Muscle ISG15 Overexpression in Juvenile Inflammatory Myopathies. Arthritis Rheumatol 2021;73:1044-52. [DOI: 10.1002/art.41625] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
42 Wu W, Xu W, Sun W, Zhang D, Zhao J, Luo Q, Wang X, Zhu F, Zheng Y, Xue Y, Wan W, Wu H, Han Q, Ye S. Forced vital capacity predicts the survival of interstitial lung disease in anti-MDA5 positive dermatomyositis: a multi-centre cohort study. Rheumatology (Oxford) 2021:keab305. [PMID: 33764398 DOI: 10.1093/rheumatology/keab305] [Cited by in Crossref: 1] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
43 Hou C, Authier FJ, Gitiaux C. Reply. Arthritis Rheumatol 2021;73:1566-7. [PMID: 33645888 DOI: 10.1002/art.41706] [Reference Citation Analysis]
44 Hodgkinson LM, Wu TT, Fiorentino DF. Dermatomyositis autoantibodies: how can we maximize utility? Ann Transl Med 2021;9:433. [PMID: 33842654 DOI: 10.21037/atm-20-5175] [Cited by in F6Publishing: 9] [Reference Citation Analysis]
45 Toquet S, Granger B, Uzunhan Y, Mariampillai K, Nunes H, Benveniste O, Allenbach Y. The seasonality of Dermatomyositis associated with anti-MDA5 antibody: An argument for a respiratory viral trigger. Autoimmun Rev 2021;20:102788. [PMID: 33609802 DOI: 10.1016/j.autrev.2021.102788] [Cited by in Crossref: 1] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
46 Li Y, Li Y, Wu J, Miao M, Gao X, Cai W, Shao M, Zhang X, Xu Y, Cong L, He J, Sun X. Predictors of Poor Outcome of Anti-MDA5-Associated Rapidly Progressive Interstitial Lung Disease in a Chinese Cohort with Dermatomyositis. J Immunol Res 2020;2020:2024869. [PMID: 33299896 DOI: 10.1155/2020/2024869] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 1.0] [Reference Citation Analysis]
47 Tanboon J, Inoue M, Hirakawa S, Tachimori H, Hayashi S, Noguchi S, Suzuki S, Okiyama N, Fujimoto M, Nishino I. Pathologic Features of Anti-Mi-2 Dermatomyositis. Neurology 2021;96:e448-59. [PMID: 33277422 DOI: 10.1212/WNL.0000000000011269] [Cited by in Crossref: 3] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
48 Tanboon J, Nishino I. COVID-19-associated myositis may be dermatomyositis. Muscle Nerve 2021;63:E9-E10. [PMID: 33095493 DOI: 10.1002/mus.27105] [Cited by in Crossref: 3] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
49 Berth SH, Lloyd TE. Secondary Causes of Myositis. Curr Treat Options Neurol. 2020;22:38. [PMID: 33041620 DOI: 10.1007/s11940-020-00646-0] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
50 Gupta L, Muhammed H, Naveen R, Kharbanda R, Gangadharan H, Misra DP, Lilleker JB, Chinoy H, Agarwal V. Insights into the knowledge, attitude and practices for the treatment of idiopathic inflammatory myopathy from a cross-sectional cohort survey of physicians. Rheumatol Int 2020;40:2047-55. [PMID: 32880031 DOI: 10.1007/s00296-020-04695-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
51 Tanboon J, Uruha A, Stenzel W, Nishino I. Where are we moving in the classification of idiopathic inflammatory myopathies? Current Opinion in Neurology 2020;33:590-603. [DOI: 10.1097/wco.0000000000000855] [Cited by in Crossref: 12] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
52 Nguyen M, Do V, Yell PC, Jo C, Liu J, Burns DK, Wright T, Cai C. Distinct tissue injury patterns in juvenile dermatomyositis auto-antibody subgroups. Acta Neuropathol Commun 2020;8:125. [PMID: 32758284 DOI: 10.1186/s40478-020-01007-3] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
53 Duchesne M, Leonard-Louis S, Landon-Cardinal O, Anquetil C, Mariampillai K, Monzani Q, Benveniste O, Allenbach Y. Edematous myositis: a clinical presentation first suggesting dermatomyositis diagnosis. Brain Pathol 2020;30:867-76. [PMID: 32323412 DOI: 10.1111/bpa.12844] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Tiniakou E. Statin-Associated Autoimmune Myopathy: Current Perspectives. Ther Clin Risk Manag 2020;16:483-92. [PMID: 32581543 DOI: 10.2147/TCRM.S197941] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
55 Monseau G, Landon-Cardinal O, Stenzel W, Schoindre Y, Mariampillai K, Barete S, Martel C, Masseau A, Meyer A, Terrier B, Guégan S, Verneuil L, Audia S, Livideanu CB, Hachulla E, Kahn JE, Lefevre G, Maurier F, Moulis G, Papo T, Dossier A, Descamps V, Salort-Campana E, Richard MA, Bergot E, Mortier L, Costedoat-Chalumeau N, Genot S, Perez F, Piette AM, Samson M, Schleinitz N, Zénone T, Lacoste M, de Boysson H, Madaule S, Rigolet A, Champtiaux N, Hervier B, Bouvier AM, Jooste V, Léonard-Louis S, Maisonobe T, Aouba A, Benveniste O, Bienvenu B, Allenbach Y; French Myositis Network. Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy. J Am Acad Dermatol 2020;83:1759-63. [PMID: 32244015 DOI: 10.1016/j.jaad.2020.03.058] [Cited by in Crossref: 6] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]